Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

被引：90

作者：

Atrash, S. ^{[1
]}

Tullos, A. ^{[1
]}

Panozzo, S. ^{[1
]}

Bhutani, M. ^{[2
]}

Van Rhee, F. ^{[1
]}

Barlogie, B. ^{[1
]}

Usmani, S. Z. ^{[2
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA

[2] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC 28202 USA

来源：

BLOOD CANCER JOURNAL | 2015年 / 5卷

关键词：

SINGLE-AGENT CARFILZOMIB; BORTEZOMIB; INHIBITOR; HEART;

D O I：

10.1038/bcj.2014.93

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：e272 / e272

页数：3

共 15 条

[1]

[Anonymous], ANN ONCOL S5

[2]

[Anonymous], KYPR PRESCR INF

[3] Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome [J].

Demo, Susan D. ;

Kirk, Christopher J. ;

Aujay, Monette A. ;

Buchholz, Tonia J. ;

Dajee, Maya ;

Ho, Mark N. ;

Jiang, Jing ;

Laidig, Guy J. ;

Lewis, Evan R. ;

Parlati, Francesco ;

Shenk, Kevin D. ;

Smyth, Mark S. ;

Sun, Congcong M. ;

Vallone, Marcy K. ;

Woo, Tina M. ;

Molineaux, Christopher J. ;

Bennett, Mark K. .

CANCER RESEARCH, 2007, 67 (13) :6383-6391

[4] Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database [J].

Honton, Benjamin ;

Despas, Fabien ;

Dumonteil, Nicolas ;

Rouvellat, Caroline ;

Roussel, Murielle ;

Carrie, Didier ;

Galinier, Michel ;

Montastruc, Jean Louis ;

Pathak, Atul .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 (03) :349-352

[5] The role of the proteasome in heart disease [J].

Li, Yi-Fan ;

Wang, Xuejun .

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2011, 1809 (02) :141-149

[6] Unexpected cardiotoxicity in haematological bortezomib treated patients [J].

Orciuolo, Enrico ;

Buda, Gabriele ;

Cecconi, Nadia ;

Galimberti, Sara ;

Versari, Daniele ;

Cervetti, Giulia ;

Salvetti, Antonio ;

Petrini, Mario .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (03) :396-397

[7] Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer [J].

Papandreou, CN ;

Daliani, DD ;

Nix, D ;

Yang, H ;

Madden, T ;

Wang, XM ;

Pien, CS ;

Millikan, RE ;

Tu, SM ;

Pagliaro, L ;

Kim, J ;

Adams, J ;

Elliott, P ;

Esseltine, D ;

Petrusich, A ;

Dieringer, P ;

Perez, C ;

Logothetis, CJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2108-2121

[8] Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome [J].

Parlati, Francesco ;

Lee, Susan J. ;

Aujay, Monette ;

Suzuki, Erika ;

Levitsky, Konstantin ;

Lorens, James B. ;

Micklem, David R. ;

Ruurs, Paulina ;

Sylvain, Catherine ;

Lu, Yan ;

Shenk, Kevin D. ;

Bennett, Mark K. .

BLOOD, 2009, 114 (16) :3439-3447

[9]

Raats M. M., 1992, Food Quality and Preference, V3, P89, DOI 10.1016/0950-3293(91)90028-D

[10] Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies [J].

Siegel, David ;

Martin, Thomas ;

Nooka, Ajay ;

Harvey, R. Donald ;

Vij, Ravi ;

Niesvizky, Ruben ;

Badros, Ashraf Z. ;

Jagannath, Sundar ;

McCulloch, Leanne ;

Rajangam, Kanya ;

Lonial, Sagar .

HAEMATOLOGICA, 2013, 98 (11) :1753-1761

← 1 2 →